secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001641172-25-019760
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics stockholders approve reverse stock split and director elections at 2025 meeting
--------------------------------------------------------------------------------

- Stockholders elected Mary Fisher and Andrew Sandler as Class I directors for three-year terms.
- Ratified Baker Tilly US, LLP as independent auditor for FY2025 with 3,229,829 votes for.
- Approved issuance of shares underlying warrants from Jan 2025 SPA and March 2025 inducement letter (over 20% of outstanding).
- Authorized reverse stock split at ratio between 1:2 and 1:30, with board to determine exact ratio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225019760/0001641172-25-019760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225019760/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer